PDCD1 and cancer: There are several types of cancer immunotherapies that target specific antibodies: There are antibodies targeting programmed cell death protein-1 (PD-1), programmed cell death ligand (PD-L1), and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) checkpoints.